logo auris_medical_2f

Auris Medical Holding AG Announces Launch and Pricing of IPO

Auris Medical Holding AG —the developer of treatments for acute inner ear tinnitus (AM-101) and acute inner ear hearing loss (AM-111) by way of intratympanic injection—announced on August 6 pricing of its IPO. The company’s common shares have been approved for listing on the NASDAQ Global Market and are expected to begin trading under the ticker symbol “EARS”.